Market Overview

Cantor Fitzgerald Initiates Coverage On Intra-Cellular Therapies with Overweight Rating, Announces $32 Price Target

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for ITCI

DateFirmActionFromTo
Aug 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Feb 2018JP MorganInitiates Coverage OnOverweight
Feb 2018RBC CapitalInitiates Coverage OnOutperform

View More Analyst Ratings for ITCI
View the Latest Analyst Ratings

Posted-In: News Initiation Analyst Ratings

 

Related Articles (ITCI)

Dan Nathan Sees Unusual Options Activity In Electronic Arts

A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings, Economic Data